Wellgistics Health

WGRX

Market cap $33.7M

Feasibility assessment completed, PharmacyChain™ to leverage Datavault AI's edge network and quantum key encryption to improve data driven outcomes in $634 billion prescription drug market Quantum key encryption fortities pharmacies from quantum's pending encryption-busting impact on traditional encryption methods TAMPA, FLORIDA / ACCESS Newswire / January 12, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (‘AI') platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today provided an update on its strategic licensing partnership with DataVault AI, Inc. (NASDAQ:DVLT), a Pioneer in AI-driven data valuation, monetization, and secure tokenization within Web 3.0 environments. Through this partnership, Wellgistics has licensed DataVault AI's advanced technology platform to integrate proprietary blockchain-enabled tokenization and blockchain-enabled smart contract capabilities into its patented PharmacyChain™ platform.

Integration of prescription drug dispensing optimization aritifical intelligence platform EinsteinRx™ into pharmacy client point-of-sales systems has commenced EinsteinRx integration streamlining effort focuses on reducing onboarding process friction and speeding time to implementation prior to scaling pharmacy marketing effort Company expects to onboard up to 500 pharmacies per month into formal Wellgistics Pharmacy Network by year end 2026 Manufacturer supplier relationship expansion effort focused on diabetes, weight loss, cardiometabolic & Long COVID patients that existing pharmacy clients already serve PharmacyChain™ blockchain-enabled healthcare smart contract development resource assessment ongoing TAMPA, FLORIDA / ACCESS Newswire / January 7, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (‘AI') platform EinsteinRx ™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today provided a corporate outlook for 2026 to stakeholders. "Three months following my return to the role of President at Wellgistics, the Company now has a clear direction as we begin a hyper-focused operational execution phase," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health.

TAMPA, FL / ACCESS Newswire / December 17, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx ™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today reminded shareholders of the December 19, 2025 record date (the "Record Date") to receive Dream Bowl 2026 Meme Coin ("Dream Bowl") tokens. All eligible record holders of Wellgistics Health, Inc. common stock will receive one (1) Dream Bowl token for every one (1) share of common stock owned.

Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash price Proprietary EinsteinRx™ artificial intelligence pharmacy platform empowers the 6,500+ pharmacies in the Wellgistics Pharmacy Network to educate patients and providers on the advantages of Brenzavvy vs. Jardiance® and other SGLT-2 inhibitors Reduced out-of-pocket costs for patients, paired with a patient-education revenue opportunity for pharmacists, are designed to support broader market access to Brenzavvy and enhance the overall care experience Launch establishes a new model for next-generation reformulated drugs that offer patient-specific product advantages compared with entrenched market leaders TAMPA, FL / ACCESS Newswire / December 8, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx ™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that it has begun the commercial launch of diabetes prescription drug Brenzavvy® to its network of 6,500 independent pharmacies (the "Wellgistics Pharmacy Network") that primarily target patients in rural communities where there is often an increased incidence of diabetes.

TAMPA, FLORIDA / ACCESS Newswire / December 4, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader implementing EinsteinRx™ artificial intelligence prescription drug routing into blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription medicines reimbursement and dispensing journey, today announced that it set a record date of December 19, 2025 for determining stockholders entitled to receive the Dream Bowl 2026 Meme Coin. Shareholders will receive one (1) Dream Bowl 2026 Meme Coin from every one (1) share of Wellgistics Health owned upon the record date.

Company plans to distribute Dream Bowl 2026 Meme Coin to shareholders as of a to-be-determined December 2025 date with distribution expected in January 2026 TAMPA, FLORIDA / ACCESS Newswire / November 26, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader implementing EinsteinRx™ artificial intelligence prescription routing for the physical dispensing of prescription drugs with PharmacyChain™ blockchain-enabled smart contracts to optimize the tracking, dispending and insurance coverage of prescription pharmaceutical drugs from manufacturer to dispensing from pharmacy to patient, today announced that it is sponsoring Dream Bowl 2026 and participation in the DataVault AI (NASDAQ:DVLT) Shareholder Distribution Plan. The Company expects to set (1) a record date and (2) a distribution date for the Dream 2026 Meme Coin to its shareholders; both are expected to occur in December 2025.

TAMPA, FL / ACCESS Newswire / November 20, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader at the nexus of serialization of healthcare technology infrastructure into the individual patient fulfillment of prescription drug through pharmacies ‘From Manufacturer To Patient', today reported financial results for the period ended September 30, 2025 on Form 10-Q on November 19, 2025 [1] and provided a business update from the CEO. "The last 6 weeks have really allowed me to understand the different stages of development of the various parts of the business after I was reappointed as President and given the title of Interim-CEO on October 6, 2025," said Prashant Patel, RPh, President and Interim-CEO of Wellgistics Health.

TAMPA, FL / ACCESS Newswire / November 17, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader at the nexus of the physical and technology healthcare infrastructures for prescription drug distribution from manufacturer to patient through licensed pharmacies, today announced that it will report third quarter 2025 provide a business update and report financial results for the period ended September 30, 2025 on the morning of Thursday, November 20, 2025. About Wellgistics Health, Inc. Wellgistics Health (NASDAQ:WGRX) is pharmacy physical and technology enabling health IT company that specializes in optimizing the delivery medications from manufacturers to patients.

Company to offer the first clinically validated dietary management of sarcopenia, now available for GLP-1 muscle loss, positioning Wellgistics to help 6,500+ independent pharmacy network (‘Pharmacy Network') and telehealth partners mitigate patient muscle loss in the GLP-1 drug market, estimated to grow to $150 billion by 2030 Company to offer first SARS-CoV-2 related natural antiviral combo for Long COVID with addition of 3CL protease inhibitor supplement Tollovid® to Galectovid 1 & 3 inhibitor Medical Food Galectovid® distribution agreement to Pharmacy Network & physicians TAMPA, FLORIDA / ACCESS Newswire / November 14, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a leader in the integration of physical and technology healthcare infrastructure for prescription drugs, today announced that it has expanded its agreement with Tollo Health to offer the first GLP-1 companion muscle loss medical food to its 6,500+ independent pharmacy network (‘Pharmacy Network') and physicians. The product is a branded version of a proprietary formulation that has been widely studied in metabolic dysfunction, with patients presenting diabetes type 2, heart failure, and COPD.

Consolidates messaging around Einstein Rx AI, Wellgistics Hub (formerly DelivMeds) and HubRx AI integration with pharmacies (in-house pharmacy and 6,500+ independent pharmacy network), physicians and manufacturers Integration of technology and physical infrastructure positions Wellgistics with the "Pharmacy IT Railroad" to execute on PharmacyChain™ smart contracts for optimized healthcare delivery in the $634 billion United States prescription drug market TAMPA, FL / ACCESS Newswire / November 12, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a leader in the integration of physical and technology healthcare infrastructure for prescription drugs, today announced that it has launched EinsteinRx™, the premier prescription management solution to integrate physical and technology infrastructure for the prescription drug industry. EinsteinRx allows for the fully customizable, seamless flow of information from the physician to the pharmacy, integrating drug manufacturing data, insurance information, patient data, nutritional recommendations and prescription fulfillment data in order to deliver an optimal solution for all key stakeholders.